Axovant Sciences is capitalizing on the attention it has received from welcoming biotech icon David Hung as its new CEO with a $125 million share offering.
Move over Sanofi, your original $9.3 billion bid and even your second, sweetened offer has been blown out of the water by the $14 billion being put on the table by Pfizer--and Medivation’s CEO David Hung has decided that's his best bet and has taken the deal.